THE ROLE OF OMEGA-3 FATTY ACIDS AND EZETIMIBE IN REDUCING TRIGLYCERIDES AND CARDIOVASCULAR RISK

Authors

  • Dr Asaf Syed
  • Dr Aakif Javed Khan
  • Dr Fida Muhammad Khan
  • Dr Muhammad Hassan Khan
  • Dr Khayyam Haider
  • Dr Mohammad Sajjad

DOI:

https://doi.org/10.53555/4fd10q32

Keywords:

Omega-3 Fatty Acids, Ezetimibe, Triglycerides, Cardiovascular Risk, Lipid Profiles, Combination Therapy

Abstract

Introduction: Globally, cardiovascular disease (CVD) still ranks as the main cause of mortality; dyslipidemia is a prominent risk factor with modifiable influence. Low-density lipoprotein cholesterol (LDL-C) and elevated triglycerides are clearly important elements in raising the risk of cardiovascular disease in those with lipid problems.

Objective: To evaluate the collective effectiveness of Omega-3 fatty acids and Ezetimibe in decreasing triglyceride levels and lowering the risk of cardiovascular disease.

Methodology: This research used a randomized controlled trial methodology, which included 200 individuals. The participants were placed into four groups: Omega-3 fatty acids, Ezetimibe, Combination treatment, and Placebo. Subjects were administered their designated therapies on a daily basis for a duration of 12 months, while undergoing frequent assessments at the beginning, 3 months, 6 months, and 12 months. At each time point, many key outcomes were assessed, such as triglycerides, LDL-C, HDL-C, CRP, and Lp(a) levels. A statistical analysis to examine the impact of the therapies on lipid profiles and indicators of cardiovascular risk.

Results: The Combination treatment demonstrated the most notable decreases, reducing triglycerides by 21.7% (from 180 ± 25 mg/dL to 140 ± 18 mg/dL) and LDL-C by 24.2% (from 120 ± 15 mg/dL to 90 ± 12 mg/dL). This treatment demonstrated superior efficacy compared to Omega-3 or Ezetimibe used alone. In addition, the Combination treatment significantly enhanced HDL-C levels by 17.9%, which much exceeded the minor alterations seen in the Placebo group.

Conclusion: Combining Omega-3 fatty acids and Ezetimibe offers superior lipid-lowering effects, potentially leading to a greater reduction in cardiovascular risk.

Author Biographies

  • Dr Asaf Syed

    House Officer, Internal Medicine (Cardiology), Ayub Teaching Hospital, Abbottabad, Pakistan

  • Dr Aakif Javed Khan

    House Officer, Ayub Teaching Hospital, Abbottabad, Pakistan

  • Dr Fida Muhammad Khan

    Resident, Internal Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan

  • Dr Muhammad Hassan Khan

    House Officer, Lady Reading Hospital, Peshawar Pakistan

  • Dr Khayyam Haider

    House Officer, General Surgery, Lady Reading Hospital, Peshawar, Pakistan

  • Dr Mohammad Sajjad

    Assistant Professor and HOD, Department of Community Medicine, Gajju Khan Medical College, Shamansoor Medical Hospital, Swabi, Pakistan

References

1. Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019 Apr 15;18(1):48. doi: 10.1186/s12933-019-0851-z. PMID: 30987625; PMCID: PMC6466658.

2. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011 Dec;13(6):544-52. doi: 10.1007/s11886-011-0220-3. PMID: 21968696; PMCID: PMC3234107.

3. Krupa KN, Fritz K, Parmar M. Omega-3 Fatty Acids. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564314/

4. Bornfeldt KE. Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines. J Clin Invest. 2021 Mar 15;131(6):e147558. doi: 10.1172/JCI147558.

5. Weber, P., & Raederstorff, D. (2000). Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids--a review. Nutrition, metabolism, and cardiovascular diseases : NMCD, 10(1), 28–37. https://pubmed.ncbi.nlm.nih.gov/10812585/

6. Sheikh O, Vande Hei AG, Battisha A, Hammad T, Pham S, Chilton R. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019 Jun 24;18(1):84. doi: 10.1186/s12933-019-0887-0. PMID: 31234885; PMCID: PMC6591979.

7. Mohebi-Nejad A, Bikdeli B. Omega-3 supplements and cardiovascular diseases. Tanaffos. 2014;13(1):6-14. PMID: 25191488; PMCID: PMC4153275.

8. Kris-Etherton, P. M., Harris, W. S., Appel, L. J., & AHA Nutrition Committee. American Heart Association (2003). Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology, 23(2), 151–152. https://doi.org/10.1161/01.atv.0000057393.97337.ae

9. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-333. https://doi.org/10.1161/CIR.0b013e3182160726

10. Patel SB. Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr Cardiol Rep. 2004 Nov;6(6):439-42. doi: 10.1007/s11886-004-0052-5. PMID: 15485605; PMCID: PMC1237023.

11. Nutescu, E. A., & Shapiro, N. L. (2003). Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy, 23(11), 1463–1474. https://doi.org/10.1592/phco.23.14.1463.31942

12. Choi H, Kang SH, Jeong SW, Yoon CH, Youn TJ, Song WH, Jeon DW, Lim SW, Lee JH, Cho SW, Chae IH, Kim CH. Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea. J Lipid Atheroscler. 2023 Sep;12(3):277-289. doi: 10.12997/jla.2023.12.3.277. Epub 2023 Aug 3. PMID: 37800112; PMCID: PMC10548190.

13. Lee J, Egolum U, Parihar H, Cooley M, Ling H. Effect of Ezetimibe Added to High-Intensity Statin Therapy on LDL-C Levels: A Meta-Analysis. Cardiol Res. 2021 Apr;12(2):98-108. doi: 10.14740/cr1224. Epub 2021 Feb 23. PMID: 33738013; PMCID: PMC7935639.

14. Malham SB, Goldberg AC. Cardiovascular risk reduction: the future of cholesterol lowering drugs. Current opinion in pharmacology. 2016 Apr 1;27:62-9. https://doi.org/10.1016/j.coph.2016.01.007

15. Masana L, Ibarretxe D, Plana N. Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy. Curr Cardiol Rep. 2020 Jun 19;22(8):66. doi: 10.1007/s11886-020-01326-w. PMID: 32562015; PMCID: PMC7305062.

16. Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Current opinion in lipidology. 2009 Feb 1;20(1):30-8. http://dx.doi.org/10.1097/MOL.0b013e328321b3be

17. Swarne E, Srikanth MS, Shreyas A, Desai S, Mehdi S, Gangadharappa HV, Krishna KL. Recent advances, novel targets and treatments for cholelithiasis; a narrative review. European Journal of Pharmacology. 2021 Oct 5;908:174376. https://doi.org/10.1016/j.ejphar.2021.174376

18. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015 Jun 18;372(25):2387-97. DOI: 10.1056/NEJMoa1410489

19. Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr. 2010 Jun 7;2:34. doi: 10.1186/1758-5996-2-34. PMID: 20529243; PMCID: PMC2902423.

20. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. [Updated 2022 Mar 7]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326741/

21. Kayani T, Ahmad B, Chang RS, Qian F, Sahinoz M, Rehan MW, Giaimo A, Spatz ES, Hu JR. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease. Pharmacoepidemiology. 2024 Mar 5;3(1):117-68. https://doi.org/10.3390/pharma3010009

22. Li JJ, Dou KF, Zhou ZG, Zhao D, Ye P, Zhao JJ, Guo LX. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts' Committee Of National Society Of Cardiometabolic Medicine. Front Pharmacol. 2022 Dec 12;13:1069992. doi: 10.3389/fphar.2022.1069992. PMID: 36578548; PMCID: PMC9791266.

23. Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Are We Using Ezetimibe As Much As We Should?. Biomarker Insights. 2024 May;19:11772719241257410. https://doi.org/10.1177/11772719241257410

24. Skulas-Ray AC, Wilson PW, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019 Sep 17;140(12):e673-91. https://doi.org/10.1161/CIR.0000000000000709

Downloads

Published

2024-08-24

How to Cite

Dr Asaf Syed, Dr Aakif Javed Khan, Dr Fida Muhammad Khan, Dr Muhammad Hassan Khan, Dr Khayyam Haider, & Dr Mohammad Sajjad. (2024). THE ROLE OF OMEGA-3 FATTY ACIDS AND EZETIMIBE IN REDUCING TRIGLYCERIDES AND CARDIOVASCULAR RISK. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 2013-2020. https://doi.org/10.53555/4fd10q32
More Citation Formats

Issue

Section

Articles

How to Cite

Dr Asaf Syed, Dr Aakif Javed Khan, Dr Fida Muhammad Khan, Dr Muhammad Hassan Khan, Dr Khayyam Haider, & Dr Mohammad Sajjad. (2024). THE ROLE OF OMEGA-3 FATTY ACIDS AND EZETIMIBE IN REDUCING TRIGLYCERIDES AND CARDIOVASCULAR RISK. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 2013-2020. https://doi.org/10.53555/4fd10q32

Most read articles by the same author(s)